922sek
1,2 %
Date:2025-05-14Time:18:00:00Latest report:Q2-2025List:First NorthTicker:DMYD B
Market Cap:1 269 msekEnterprise Value:1 165 msekNet Sales:0,18 msekEarnings:-170,8 msekEmployees:0ISIN:SE0005162880

Ratios

10-year key figure history for Diamyd Medical turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Diamyd Medical with index and moving average MA50 and MA200.

Stockprice:9,22
MA50:8,47
MA200:13,74
Price/MA200:-32,9 %
RSI (14):58,2
Price/MA50:8,8 %

Description

Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.

Biotechnology